Sarcoidosis decisions — 2025

The Board remands the issues related to the Veteran's eye disabilities for further development, including obtaining a VA examination and medical opinions.

The Board denied service connection for multiple respiratory conditions, including sarcoidosis, bronchial asthma, COPD, chronic rhinitis, chronic sinusitis, emphysema, and tuberculosis pleurisy.

The Board remands the claim for service connection for a respiratory condition, claimed as sarcoidosis and chronic bronchitis, due to missing records and inadequate medical opinions.

The Board remands the claims for service connection for sarcoidosis, right and left fingers disabilities, and a cardiac disability due to insufficient development of evidence regarding in-service exposure to herbicide agents or other toxic substances.

The Board remands the veteran's claims for service connection for various conditions, including diabetes mellitus, type II, uveitis of the right eye with increased ocular pressure and defective vision, increased ocular pressure of the left eye with defective vision, hypertension, a respiratory disorder (claimed as asthmatic bronchitis), a skin disability, sarcoid arthritis, chest pain, and an acquired psychiatric disability, to obtain new VA examinations.

The appeal was dismissed as the Veteran withdrew all claims, including the instant appeal, on January 27, 2025.

The Board dismissed the veteran's appeals for an increased rating and service connection due to premature filing of a VA Form 10182 before the AOJ had adjudicated the issues.

The Board granted service connection for pulmonary sarcoidosis, restoring it after finding that the severance was improper. The appeal is also remanded to determine if allergic rhinitis and kidney disease are related to service.

The Board remands the claims for service connection due to a need to verify potential herbicide exposure at Fort McClellan.

The Board denied service connection for obstructive sleep apnea and remanded the claim for cardiac sarcoidosis due to inadequate VA opinions.

The Board denied service connection for obstructive sleep apnea, sarcoidosis, and bradycardia as the evidence did not show a relationship between these conditions and the Veteran's active service.

The Board granted service connection for bronchitis and increased the rating for asthma with COPD to 60 percent, while denying service connection for hyperthyroidism, sarcoidosis, a lung condition other than asthma, TDIU from July 29, 2016, to March 15, 2017, and special monthly compensation (SMC) based upon aid and attendance/housebound status.

The appeal was dismissed due to the Veteran's death during the pendency of the appeal.

The Board denied the Veteran's claim for an initial compensable rating for sarcoidosis as the evidence did not support a finding of pulmonary involvement with persistent symptoms requiring chronic low dose or intermittent corticosteroids, nor FEV-1 or FEV-1/FVC results within the range that would warrant a compensable rating.

The Board denied service connection for pleurisy, sarcoidosis, and an increased rating for allergic rhinitis as the evidence did not support a finding of current disability or in-service incurrence.

The Board denied service connection for hypertension, diabetes mellitus, type II (diabetes), and allergic rhinitis, as well as an initial compensable disability rating for sarcoidosis.

The Board remands the claim for service connection for an autoimmune-related disability, to include sarcoidosis and/or scleroderma, due to insufficient evidence.

The Board remands the claims for further development, including providing notice of the Veteran's right to a hearing and determining whether an examination is necessary.

The Board denied service connection for a low back condition, diabetes mellitus, type II (DMII), and bilateral hearing loss. However, it granted an initial rating of 20 percent for bilateral cataracts.

The Board denied the Veteran's claim for service connection for sarcoidosis and remanded claims for service connection for right and left knee degenerative arthritis.